BUSINESS
Sanofi Looks to Join Top 3 in Japan Pharma Market by 2030
April 25, 2025
Sanofi aims to become a top three pharmaceutical company in terms of Japan revenue by 2030 by continuing its double-digit growth towards the end of the decade, the company’s country president Takahiko Iwaya said on…

LATEST

April 28, 2025
Sanofi said on April 25 that it has filed its IL-4/IL-13 inhibitor Dupixent (dupilumab) for an additional indication of bullous pemphigoid in Japan. If approved, the drug will be the country’s first biologic agent to…
April 28, 2025
ASKA Pharmaceutical’s contraceptive pill drospirenone cleared the review of a key health ministry panel on April 25, along with the label expansions of two products, setting the stage for Japanese regulatory approval.The Pharmaceutical Affairs Council’s…
April 25, 2025
While talks of consumption tax cuts swirl in Japan ahead of the Upper House election this summer, lawmakers of the ruling Liberal Democratic Party (LDP) made no clear demand for reducing the rate of such…
By Takashi Ebisawa

Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…

By Philip Carrigan

Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

By Ken Yoshino

Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA